AMENDMENTS TO THE CLAIMS

Claims 1-11 (cancelled)

Claim 12 (Currently amended): A composition for treating herpes group viral infections, said composition comprising activated autologous lymphocytes effective against ~~said~~ and specific for herpes group viral infections, said activated autologous lymphocytes being obtained by culturing autologous lymphocytes derived from a herpes group virally infected patient, or an immunodeficient or immunosuppressed patient due to herpes group viral infection, in a culture medium comprising anti-CD3 antibodies in a solid phase and interleukin-2 to proliferate and activate *in vitro* said autologous lymphocytes, said virally infected patient or said immunodeficient or immunosuppressed patient to be provided with said composition.

Claim 13 (Currently amended): A method for preparing a composition for treating herpes group viral infections, said method comprising deriving autologous lymphocytes from a herpes group virally infected patient or an immunodeficient or immunosuppressed patient due to herpes group viral infection, to be provided with said composition, and culturing said autologous lymphocytes in a culture medium comprising anti-CD3 antibodies in a solid phase and interleukin-2 to proliferate and activate *in vitro* said autologous lymphocytes which are effective against and specific for herpes group viral infections.

Claim 14 (Currently amended): A method for treating herpes group viral infections, said method comprising deriving autologous lymphocytes from a herpes group virally infected patient, or an immunodeficient or immunosuppressed patient due to herpes group viral infection, culturing said autologous lymphocytes in a culture medium comprising anti-CD3 antibodies in a solid phase and interleukin-2 to proliferate and activate *in vitro* said autologous lymphocytes, and administering said activated autologous lymphocytes which are effective against and specific for

herpes group viral infections to said patient from which said autologous lymphocytes were derived.

Claim 15 (Previously presented): The composition according to claim 12, wherein said activated autologous lymphocytes cultivated *in vitro* are suspended in a buffer solution of physiological saline or phosphate buffer solution to make a cell-suspended solution, and administered to said patient.

Claim 16 (Previously presented): The composition according to claim 15, wherein a protein is added to said cell-suspended solution.

Claim 17 (Previously presented): The composition according to claim 16, wherein said protein is human albumin.

Claim 18 (Previously presented): The composition according to claim 12, wherein said culture medium further comprises cytokines.

Claim 19 (Previously presented): The method according to claim 13, wherein said activated autologous lymphocytes cultivated *in vitro* are suspended in a buffer solution of physiological saline or phosphate buffer solution to make a cell-suspended solution, and administered to said patient.

Claim 20 (Previously presented): The method according to claim 19, wherein a protein is added to said cell-suspended solution.

Claim 21 (Previously presented): The method according to claim 20, wherein said protein is human albumin.

Claim 22 (Previously presented): The method according to claim 13, wherein said culture medium further comprises cytokines.

Claim 23 (Previously presented): The method according to claim 14, wherein said activated autologous lymphocytes cultivated *in vitro* are suspended in a buffer solution of physiological saline or phosphate buffer solution to make a cell-suspended solution, and administered to said patient.

Claim 24 (Previously presented): The method according to claim 23, wherein a protein is added to said cell-suspended solution.

Claim 25 (Previously presented): The method according to claim 24, wherein said protein is human albumin.

Claim 26 (Previously presented): The method according to claim 23, wherein said activated autologous lymphocytes having a cell concentration in the range of 1×10^4 parts/lit. to 1×10^8 parts/lit. are administered to same patient at a time.

Claim 27 (Previously presented): The method according to claim 23, wherein said culture medium further comprises cytokines.

Claim 28 (Cancelled)

Claim 29 (Previously presented): The composition according to claim 12, wherein said herpes group viral infection is an Epstein-Barr virus infection.

Claim 30 (Cancelled)

Claim 31 (Previously presented): The method according to claim 13, wherein said herpes group viral infection is an Epstein-Barr virus infection.

Claim 32 (Previously presented): The method according to claim 14, wherein said patient is virally infected, immunodeficient or immunosuppressed due to an Epstein-Barr virus infection.

Claim 33 (Previously presented): The composition according to claim 29, wherein said herpes group viral infection is a herpes simplex virus infection.

Claim 34 (Previously presented): The method according to claim 13, wherein said herpes group viral infection is a herpes simplex virus infection.

Claim 35 (Previously presented): The composition according to claim 12, wherein the activated autologous lymphocytes are T-lymphocytes.

Claim 36 (Previously presented): The method according to claim 13, wherein the activated autologous lymphocytes are T-lymphocytes.

Claim 37 (Previously presented): The method according to claim 14, wherein the activated autologous lymphocytes are T-lymphocytes.